WO2009025149A1 - Adnf receptor - Google Patents

Adnf receptor Download PDF

Info

Publication number
WO2009025149A1
WO2009025149A1 PCT/JP2008/063428 JP2008063428W WO2009025149A1 WO 2009025149 A1 WO2009025149 A1 WO 2009025149A1 JP 2008063428 W JP2008063428 W JP 2008063428W WO 2009025149 A1 WO2009025149 A1 WO 2009025149A1
Authority
WO
WIPO (PCT)
Prior art keywords
adnf
amino acid
receptor
acid sequence
seq
Prior art date
Application number
PCT/JP2008/063428
Other languages
French (fr)
Japanese (ja)
Inventor
Masaaki Matsuoka
Sadakazu Aiso
Tomo Nishimoto
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Publication of WO2009025149A1 publication Critical patent/WO2009025149A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

The object is to identify a receptor for ADNF to elucidate a specific signaling pathway of the anti-ALS activity of ADNF, and to provide a screening system for identifying a compound capable of binding to the ADNF receptor or a compound capable of inhibiting or enhancing the binding between ADNF and the ADNF receptor or the like. Disclosed is an ADNF receptor comprising a polypeptide having any one of the following amino acid sequences (1) to (3): (1) the amino acid sequence depicted in SEQ ID NO:2 or 3; (2) an amino acid sequence having the deletion, substitution or insertion of one or several amino acid residues in the amino acid sequence depicted in SEQ ID NO:2 or 3; and (3) an amino acid sequence having a 70% or more homology with the amino acid sequence depicted in SEQ ID NO:2 or 3.
PCT/JP2008/063428 2007-08-23 2008-07-25 Adnf receptor WO2009025149A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007216664A JP2009046459A (en) 2007-08-23 2007-08-23 Adnf receptor
JP2007-216664 2007-08-23

Publications (1)

Publication Number Publication Date
WO2009025149A1 true WO2009025149A1 (en) 2009-02-26

Family

ID=40378057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063428 WO2009025149A1 (en) 2007-08-23 2008-07-25 Adnf receptor

Country Status (2)

Country Link
JP (1) JP2009046459A (en)
WO (1) WO2009025149A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882429B1 (en) * 2012-08-07 2024-04-10 The General Hospital Corporation Potassium-channel openers for use in treating amyotrophic lateral sclerosis (ALS)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097156A1 (en) * 2004-04-08 2005-10-20 Nishimoto, Tomo Remedy for neurodegenerative diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097156A1 (en) * 2004-04-08 2005-10-20 Nishimoto, Tomo Remedy for neurodegenerative diseases
WO2005099741A1 (en) * 2004-04-08 2005-10-27 Noevir Co., Ltd. Remedy for motoneuron diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAUER H. ET AL.: "Characterization of p40/GPR69A as a peripheral membrane protein related to the lantibiotic synthetase component C", BIOCHEM.BIOPHYS.RES.COMMUN., vol. 275, 2000, pages 69 - 74 *
BLISNICK T. ET AL.: "LANCL1, an erythrocyte protein recruited to the Maurer's clefts during plasmodium falciparum development", BIOCHEM.PARASITOL., vol. 141, 2005, pages 39 - 47 *
BRENNEMAN D.E. ET AL.: "Activity-dependant neurotrophic factor:structure-activity relationships of femtomolar-acting peptides", J.PHARMACOL.EXP.THER., vol. 285, no. 2, 1998, pages 619 - 627 *
CHIBA T. ET AL.: "Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo", J.NEUROSCI.RES., vol. 78, 2004, pages 542 - 552 *
CHUNG C.H.Y. ET AL.: "Identification of lanthionine synthase c-like protein-1 as a prominent glutathione binding protein expressed in the mammalian central nervous system", BIOCHEMISTRY, vol. 46, February 2007 (2007-02-01), pages 3262 - 3269 *
MAYER H. ET AL.: "Characterization of rat LANCL1, a novel member of the lanthionine synthase c-like protein family,highly expressed in testis and brain", GENE, vol. 269, 2001, pages 73 - 80 *

Also Published As

Publication number Publication date
JP2009046459A (en) 2009-03-05

Similar Documents

Publication Publication Date Title
IN2014CN02050A (en)
NZ591855A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2008086086A3 (en) Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
NZ602170A (en) Modified leptin polypeptides and their uses
MX2008009493A (en) Novel peptide and use thereof.
WO2009069808A1 (en) Epha4 polypeptide having novel activity and use thereof
WO2009025117A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same
WO2009047992A1 (en) Udp-glucuronyl transferase and polynucleotide encoding the same
WO2014037565A3 (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
WO2008113536A8 (en) Neurotrophic peptides
WO2008105178A1 (en) Agent for enhancing the resistance of liposome against biological component, and liposome modified with the agent
WO2007089038A8 (en) Novel phospholipase d
WO2009025149A1 (en) Adnf receptor
WO2008142664A3 (en) Exposed thymidine kinase 1 peptides, ligands and methods employing the same
NZ707637A (en) Signal biomarkers
WO2014162007A3 (en) Thymic stromal lymphopoietin fragments and uses thereof
WO2008155363A3 (en) Identification of new isoforms of the mhc-class i specific receptor cd160 and uses thereof
EP1801211A4 (en) Hla-binding peptide, dna fragment encoding the same and recombinant vector
WO2007066018A3 (en) Novel peptides and the biological use thereof
CY1111630T1 (en) CYCLING PRODUCERS
WO2005086595A3 (en) Telomere protein trf2 dna-binding domain mutant protein, telomere dna mutant and utilization of complex structure of trf2 dna-binding domain with double-stranded dna
MY150639A (en) T cell adhesion molecule and antibody thereto
WO2006123157A3 (en) Nematistatic protein
NZ593086A (en) Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791672

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791672

Country of ref document: EP

Kind code of ref document: A1